These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 3937188

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Rifampicin in experimental investigations on mice.
    Havel A, Adámek L, Simonová S.
    Antibiot Chemother; 1970; 16():406-15. PubMed ID: 5002306
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice.
    Dutta NK, Mazumdar K, Dastidar SG, Park JH.
    Int J Antimicrob Agents; 2007 Oct; 30(4):336-40. PubMed ID: 17644321
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing.
    Shenai S, Rodrigues C, Sadani M, Sukhadia N, Mehta A.
    Indian J Tuberc; 2009 Apr; 56(2):82-90. PubMed ID: 19810590
    [Abstract] [Full Text] [Related]

  • 31. [Tuberculosis treatment today].
    Nowak D, Radenbach D, Kirsten D, Magnussen H.
    Z Gesamte Inn Med; 1991 Aug; 46(10-11):404-9. PubMed ID: 1926948
    [Abstract] [Full Text] [Related]

  • 32. Significant increases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs.
    Lenaerts AJ, Johnson CM, Marrieta KS, Gruppo V, Orme IM.
    Int J Antimicrob Agents; 2005 Aug; 26(2):152-8. PubMed ID: 15953708
    [Abstract] [Full Text] [Related]

  • 33. Experimental investigations of bacteriological mechanisms in short course chemotherapy.
    Dickinson JM, Mitchison DA.
    Bull Int Union Tuberc; 1976 Aug; 51(1):79-86. PubMed ID: 829484
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
    Zimhony O, Cox JS, Welch JT, Vilchèze C, Jacobs WR.
    Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
    [Abstract] [Full Text] [Related]

  • 37. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
    Jawahar MS, Rajaram K, Sivasubramanian S, Paramasivan CN, Chandrasekar K, Kamaludeen MN, Thirithuvathas AJ, Ananthalakshmi V, Prabhakar R.
    Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
    [Abstract] [Full Text] [Related]

  • 38. [Determination of pyrazinamide susceptibility for Mycobacterium tuberculosis by use of Middlebrook culture media and comparison with results of pyrazinamidase test].
    Yamane N, Nakasone I, Yamashita K, Toyoda K, Okazawa Y.
    Rinsho Byori; 1998 May; 46(5):479-85. PubMed ID: 9627500
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
    Ahmad Z, Tyagi S, Minkowsk A, Almeida D, Nuermberger EL, Peck KM, Welch JT, Baughn AS, Jacobs WR, Grosset JH.
    Indian J Med Res; 2012 Nov; 136(5):808-14. PubMed ID: 23287128
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.